GSA Capital Partners’s Abivax ABVX Stock Holding History

GSA Capital Partners’s Portfolio ABVX Stock Details ABVX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$419K	Buy	3,142 +1,285	+69%	+$145K	0.03%	1116
2026 Q1	$207K	Buy	+1,857	New	+$220K	0.01%	1441

Other funds holding ABVX

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Helikon Investments London, United Kingdom $3.35B AUM 55.08% 1-Year Est. Return

DGM

Darwin Global Management St. Helier, Jersey $3.76B AUM 342.13% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Jupiter Topco New York $245B AUM

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

GSA Capital Partners's ABVX Position: Q2 2026 in Review

GSA Capital Partners increased its Abivax (ABVX) stake by 69% in Q2 2026, buying an estimated $145K and bringing the position to 3,142 shares worth $419K. The position accounts for 0.03% of the portfolio, ranked #1116.

GSA Capital Partners first reported a position in ABVX in Q1 2026 and has held it in 2 quarters since. 303 funds tracked by Wall St. Rank hold ABVX as of Q2 2026.

GSA Capital Partners held 3,142 shares of Abivax worth $419K as of Q2 2026.
GSA Capital Partners bought 1,285 Abivax shares in Q2 2026, an estimated $145K.
Abivax made up 0.03% of GSA Capital Partners's portfolio in Q2 2026, its #1116 holding.
GSA Capital Partners first reported a position in Abivax in Q1 2026 and has held it in 2 quarters since.
303 funds tracked by Wall St. Rank held Abivax as of Q2 2026.

Based on GSA Capital Partners's 13F filing for Q2 2026, filed 6 Aug 2026.